Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
Trial record 42 of 529 for:    ALS (Amyotrophic Lateral Sclerosis)

Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis (TRACK-ALS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02559869
Recruitment Status : Recruiting
First Posted : September 24, 2015
Last Update Posted : March 23, 2018
Sponsor:
Collaborators:
The Methodist Hospital System
Cedars-Sinai Medical Center
ALS Association
Information provided by (Responsible Party):
Nazem Atassi, Massachusetts General Hospital

Tracking Information
First Submitted Date September 23, 2015
First Posted Date September 24, 2015
Last Update Posted Date March 23, 2018
Study Start Date November 2015
Estimated Primary Completion Date January 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: September 23, 2015)
  • Measure & localize brain inflammation in people with ALS via [18F] GE-180 PET imaging. [ Time Frame: 12 months ]
    Aim 1 will be accomplished by obtaining [18F] GE-180 PET imaging from 25 people with ALS compared to 25 age, gender, and binding affinity matched healthy volunteers.
  • Define anatomical, structural, and functional changes in the brain via MRI of ALS Subjects vs. Healthy Controls at Baseline [ Time Frame: 12 months ]
    Aim 1 will be accomplished by obtaining state of-the-art MRI acquisition sequences from 50 people with ALS compared to 50 MRI age- and gender-matched healthy volunteers.
  • Determine systemic inflammatory factors that may modify the progression or other clinical or imaging correlates of ALS. [ Time Frame: 12 months ]
    Blood from 100 subjects will be studied to quantitate circulating pro- and anti-inflammatory monocyte/macrophage and T cells, with results to be correlated with neuroimaging and evaluated as potential biomarkers of disease progression.
Original Primary Outcome Measures Same as current
Change History Complete list of historical versions of study NCT02559869 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures
 (submitted: September 23, 2015)
  • Determine the longitudinal changes in brain inflammation in people with ALS in correlation with ALS severity and rate of progression. [ Time Frame: 12 months ]
    Clinical and [18F] GE-180 PET imaging data will be collected every 6 months from the 25 people with ALS for at least 12 months.
  • Determine the longitudinal changes in the anatomical, structural, and functional measures in people with ALS, and build ALS prediction models using the clinical and MRI data. [ Time Frame: 12 months ]
    Clinical and MRI data will be collected every 3 months from 50 people with ALS for at least 12 months.
Original Secondary Outcome Measures Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis
Official Title Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis
Brief Summary This is a multicenter, 18-month study, which aims to identify imaging and biofluid biomarkers in people with ALS to expand the understanding of ALS pathology, treatment targets, disease progression, and anatomical differences between different disease phenotypes. This pilot project is tailored to produce imaging tools that will allow researchers to conduct future ALS clinical trials more efficiently which may in turn impact the pace for ALS drug discovery.
Detailed Description

In this trial, approximately 200 subjects will participate in this study from 2 Northeast ALS Consortium (NEALS) centers in the United States. Fifty (50) ALS participants will be age and gender matched to 50 participants with no known neurological disorder (healthy controls). Of these, twenty five (25) ALS participants will be age (±5 years) gender and binding affinity (TSPO) matched to 25 healthy controls.

During the enrollment period 200 participants will be screened and 100 participants will ultimately be scanned. There will be a maximum allowed time of 45 days between the screening and baseline visits (1st scan). All 100 subjects will undergo MRI scanning and clinical assessment at the Baseline Visit. Healthy control participants will have no further follow-up visits once they have completed their participation in the screening and baseline visits. Only 50 subjects from this sample will undergo PET scanning. The ALS participants will return for follow-up MRI scanning and clinical assessments every three months and follow-up PET scanning every 6 months over a 12-month period.

Study Type Observational
Study Design Observational Model: Case-Control
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Retention:   Samples With DNA
Description:
iPSC Line Generation, DNA, Inflammatory Markers, Plasma, CSF
Sampling Method Non-Probability Sample
Study Population Approximately 200 subjects will be screened and approximately 100 subjects will be enrolled. Fifty (50) subjects will be diagnosed with possible, probable, probable-lab supported, or definite ALS, fifty (50) subjects will have no known neurological disease.
Condition Amyotrophic Lateral Sclerosis (ALS)
Intervention Drug: [18F] GE-180
PET Tracer Ligand
Other Names:
  • ligand
  • PET Tracer
Study Groups/Cohorts
  • Amyotrophic Lateral Sclerosis (ALS)
    Subjects will be diagnosed with possible, probable, probable-lab supported, or definite ALS.
    Intervention: Drug: [18F] GE-180
  • Healthy Controls
    Subjects with no known neurological disorder.
    Intervention: Drug: [18F] GE-180
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Recruiting
Estimated Enrollment
 (submitted: September 23, 2015)
200
Original Estimated Enrollment Same as current
Estimated Study Completion Date May 2021
Estimated Primary Completion Date January 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria

Study subjects meeting all of the following criteria will be allowed to enroll in the study:

  1. Male or female, aged 18 to 80
  2. Medically safe to undergo MRI scans
  3. Able to safely lie supine for at least 90 minutes in the opinion of the Site Investigator
  4. Capable of providing informed consent and following trial procedures
  5. Geographically accessible to the site

ALS subjects must also meet the following criteria:

  1. Sporadic or familial ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by modified El Escorial criteria
  2. ALS Cognitive Behavioral Screen score >10 on the cognitive scale and/or >32 on the behavioral scale

Those ALS subjects participating in the optional lumbar puncture portion of the study must also meet the following criteria:

1. Subjects medically able to undergo lumbar puncture (LP) as determined by the investigator (i.e., no bleeding disorder, allergy to local anesthetics, a skin infection at or near the LP site, or evidence of high intracranial pressure).

For those subjects participating in the PET scan portion of the study, subjects must also meet the following criteria:

  1. Medically safe to undergo PET scans
  2. No prior radiation exposure that exceeds the site's current guidelines
  3. No known allergy to any components of the tracer
  4. Baseline ECG values are within normal range
  5. Subjects must meet main study entry criteria

Exclusion Criteria

Study subjects meeting any of the following criteria during screening evaluations will be excluded from entry into the study:

  1. Any contraindication to undergo MRI studies such as

    1. History of a cardiac pacemaker or pacemaker wires
    2. Metallic particles in the body
    3. Vascular clips in the head
    4. Prosthetic heart valves
    5. Claustrophobia
  2. Diagnosis of Parkinson's disease or Alzheimer's disease
  3. Diagnosis of renal failure
  4. Have active or chronic autoimmune disease (such as hepatitis or HIV), infection, or taking immunosuppressive medications such as steroids, cyclophosphamide, etc.
  5. Presence of diaphragm pacing system (DPS)
  6. The presence of unstable psychiatric disease, cognitive impairment, or dementia that would impair ability of the subject to provide informed consent, according to SI judgment
  7. Pregnant women or women currently breastfeeding
  8. Anything that, in the opinion of the investigator, would place the subject at increased risk or preclude the subject's full compliance with or completion of the study

In addition, any subject meeting any of the following criteria during screening evaluations will be excluded from entry into the PET portion of the study:

  1. Radiation exposure that exceeds the site's current guidelines
  2. Low affinity TSPO binders determined by having a Thr/Thr polymorphism in the TSPO gene (rs6971) at the Screening Visit

Women of Childbearing Potential (WOCBP) For the purposes of this study, women of child bearing potential are defined as all women who are capable of becoming pregnant, unless they meet one of the following criteria:

  • 12-months post-menopausal
  • Post-hysterectomy
  • Surgically sterile
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years to 80 Years   (Adult, Older Adult)
Accepts Healthy Volunteers Yes
Contacts
Contact: Catherine Gladden 617-724-5456 cgladden@partners.org
Contact: Lindsay Pothier 617-643-5582 lmpothier@mgh.harvard.edu
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT02559869
Other Study ID Numbers 2015P000140
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Nazem Atassi, Massachusetts General Hospital
Study Sponsor Massachusetts General Hospital
Collaborators
  • The Methodist Hospital System
  • Cedars-Sinai Medical Center
  • ALS Association
Investigators
Principal Investigator: Nazem Atassi, MD, MMSc Massachusetts General Hospital
Principal Investigator: Joseph Masdeu, MD, PhD Houston Methodist Neurological Institute
PRS Account Massachusetts General Hospital
Verification Date March 2018